For the latest news and information on the coronavirus pandemic, visit the WHO website.
And vaccine manufacturers aren’t the only ones responding to White House pressure to rush to get a vaccine approved. Thethat some Chinese officials are taking Trump’s schedule seriously enough to expedite approval of their own vaccines. This revelation follows another New York Times investigation that detailed how China administered a significant number of experimental coronavirus vaccines outside of the typical testing process. Many fear that similar disregard for safety protocols could lead to early approval of a vaccine in the US.
Seven vaccine candidates are currently being tested in the US, three of which are nearing the terminal stage required for approval by the Food and Drug Administration. In view of– the virus that causes COVID-19 – was only discovered less than a year ago. Progress is actually faster than ever in infectious disease history (vaccine development takes about 10.7 years on average), despite Trump’s claim that vaccine development is being deliberately suppressed.
Here we are examining the current landscape for an evolving coronavirus vaccine. This article is updated frequently and is intended to be a general overview and not a source of medical advice. If you need more information about coronavirus testing,.
Important news about COVID-19 vaccines
The development of COVID vaccines is getting faster and faster
Various acceleration efforts are currently underway, such as the White House’s Operation Warp Speed, which aims to cut red tape in order to speed up vaccine development and be ready to distribute vaccines once they get FDA approval. So far, the U.S. government has pledged over $ 10 billion to several vaccine manufacturers for a total of 800 million vaccine doses.
Vaccines typically take around 10 to 15 years to develop and approve. This is done in four phases, which include human experiments. However, with Operation Warp Speed, approved vaccine projects cannot submit all sections of the application after completing all four phases, but can gradually submit data to the FDA.
In the meantime, the program is also funding efforts to begin making cans while clinical trials are ongoing. That is, by the time these vaccines are approved, there will already be a supply of doses that can be distributed nationally. “I would hope that companies will have delivered the hundreds of millions of doses promised by well into the second half of 2021,” said Dr. Anthony Fauci, director of the National Institute of Allergies and Infectious Diseases, told Forbes in August.
Promising coronavirus vaccines from the UK, US and China
Here’s a quick look at some of the frontrunners in the race for a vaccine against COVID-19, including where the vaccines are located, where they will be tested, and the fact that scientists believe they may, if known, be ready for widespread use.
Oxford University / AstraZeneca (Great Britain): AstraZeneca has suspended testing of its vaccine, which it began on 100,000 volunteers in at least three countries, and which was preparing to launch in the United States. The lead researcher Dr. Sarah Gilbert had originally said that they were aiming for a release in the fall of 2020, which may now be delayed. However, UK Health Secretary Matt Hancock said such a hiatus was “not necessarily” a setback.
Modern (USA): An apparent dispute with state regulators delayed large-scale human testing, but Moderna’s CEO has told Barron’s that he continues to expect the company to know if the vaccine is safe and effective by Thanksgiving and be able to distribute it in early 2021 , If this is the case.
Pfizer (USA): Although the four COVID-19 vaccine candidates are still in early human trials, two of them have been accelerated by the FDA. Pfizer’s chief business officer told US Congress that the company may be ready to file for FDA approval by October.
SinoVac (China): The vaccine is currently being tested on around 10,000 volunteers in China and around 9,000 in Brazil. Tests are to be carried out on around 1,900 test subjects in Indonesia shortly. The CEO of BioPharma, SinoVac’s Indonesian partner, expects the vaccine to be ready in early 2021.
SinoPharm (China): The state-owned company is currently testing around 15,000 volunteers in the Middle East in a test that is expected to take three to six months. Initial results suggest that the drug is safe and at least reasonably effective. SinoPharm recently built a second facility to manufacture the vaccine and doubled its capacity to around 200 million doses per year.
CanSino Biologics (China): CanSino’s vaccine is slated to begin large-scale human trials this summer and has already been approved for the Chinese military. The vaccine is based on a modified cold virus that some experts warn may be less effective than other vaccine efforts.
Will there be only one vaccine for everyone?
We probably won’t know until next year, but Fauci has suggested that several different vaccines, made and sold by different laboratories, might be required to end the pandemic. This was published in an article published in Science magazine on May 11th. He has also said that he has different vaccines for different groups of patients. For example, one vaccine for elderly or other high-risk patients, another for healthy adults, another for children, etc.
What if we never find a coronavirus vaccine?
Coronaviruses are a large class of viruses and there are currently no vaccines for any of them. While there are promising early results, there is no guarantee of a vaccine by 2021. Statistically, only about 6% of vaccine candidates ever make it to market, according to a Reuters special report.
Early evidence suggests that the coronavirus does not appear to mutate as quickly or frequently as the flu, and it is believed that the virus has not yet mutated significantly enough to disrupt vaccine development – although our knowledge may change.
The longer we go without a vaccine, the more likely the focus will be on treatments like that, which has reportedly shown promising results, and , a steroid that doctors say increases survival rates among the most serious of cases. With effective therapeutic treatments, many viruses that used to be fatal are no longer death sentences. For example, thanks to tremendous advances in treatment, patients with HIV can now expect the same life expectancy as non-HIV positive people.
Eventually the world population may reach the rate required for 60% to 70%Protecting those who are not immune, which is the ultimate goal of a vaccine.